Why don't we have all the evidence on oseltamivir? -- Godlee and Clarke 339: b5351 -- BMJ

Published 8 December 2009, doi:10.1136/bmj.b5351
Cite this as: BMJ 2009;339:b5351

Editorials
Why don’t we have all the evidence on oseltamivir?
The full data from drug trials must be available for scrutiny by the scientific community

This week the BMJ publishes an updated Cochrane review on neuraminidase inhibitors in adults with influenza.1 The review and a linked investigation undertaken jointly by the BMJ and Channel 4 News2 cast doubt not only on the effectiveness and safety of oseltamivir (Tamiflu) but on the system by which drugs are evaluated, regulated, and promoted.

In the process of updating their review, Jefferson et al found several important inconsistencies. Prompted by a reader of their previous update,3 they attempted to reconstruct the evidence from a much cited analysis on which they had based their previous conclusions. The analysis, by Kaiser et al,4 looked specifically at the effects of oseltamivir on the risk of hospital admission and complications (pneumonia and other lower respiratory tract infections) in people with influenza. Jefferson et al noted that the Kaiser analysis was funded by the drug’s manufacturer Roche and was based entirely on 10 trials . . . [Full text of this article: http://www.bmj.com/cgi/content/full/339/dec08_3/b5351]

Fiona Godlee, editor in chief1, Mike Clarke, director2

1 BMJ, London WC1H 9JP, 2 UK Cochrane Centre, Oxford

fgodlee@bmj.com

abrir aquí para acceder al documento bmj:
Why don't we have all the evidence on oseltamivir? -- Godlee and Clarke 339: b5351 -- BMJ